

To: jeffrey epstein (jeevacation@gmail.com)[jeffrey epstein (jeevacation@gmail.com)]; jeevacation@gmail.com[jeevacation@gmail.com]
From: Boris Nikolic
Sent: Fri 7/5/2013 10:38:34 PM
Subject: FW: Foundation-Series B Extension #4737545v2_LIBC - FM Gates Side Letter.doc
[side letter sig.pdf](#)

From: Robert Hesslein [mailto:████████████████████]
Sent: Friday, December 21, 2012 7:19 AM
To: Rodi Guidero
Cc: Mike Pellini; Jason Ryan; McGivern, Arthur R
Subject: Foundation-Series B Extension

Rodi:

To recap the conversation we had a few minutes ago, FMI and Gates Ventures will enter into an agreement in the form attached. This agreement provides GV with information rights that are equivalent to the information rights currently provided by FMI to Labcorp and Roche Ventures.

Mike Pellini would be happy to discuss directly with you, Boris, John, Allan or others how these rights can effectively be managed to meet GV's expectations. Mike's numbers are as follows: office-617.418.2244 and mobile-610.585.1048.

I have also attached a signature page to the proposed agreement. If time does not allow for signature by GV prior to the closing, we understand the closing can nonetheless proceed with delivery of the GV signature page to occur post-closing.

We are now planning to suggest to all investors a closing on Friday, December 28th. It is a difficult week, so please let us know if there is anything that we can do to facilitate GV's activities to make the closing as smooth as possible. Again, thanks to you and your team for all of your efforts.

Best regards,

--Bob

Robert W. Hesslein

Senior Vice President / General Counsel

Foundation Medicine, Inc.

One Kendall Square, B3501 | Cambridge, MA 02139



This communication and any files transmitted with it may contain information that is considered to be confidential, privileged and exempt from disclosure under applicable law. This message is intended for Foundation Medicine-affiliated use and that of the intended recipient only and may contain information that is protected by Foundation Medicine policies and the HIPAA Privacy Rule, 45 CFR ? 164.500. This communication is intended solely for the use of intended recipient. If you are not the intended recipient, you are hereby notified that any use, dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately and delete this message immediately. Thank you for your cooperation.